Daniel Feingold
Overview
Explore the profile of Daniel Feingold including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
65
Citations
841
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Loewenstein A, Asper A, Feingold D
J Psychoactive Drugs
. 2025 Mar;
:1-10.
PMID: 40087152
Combat veterans are highly inclined to develop substance use disorders, including Cannabis Use Disorder (CUD), with emerging evidence suggesting that combat related Potentially Morally Injurious Events (PMIEs) may increase proneness...
2.
Hoch E, Murawski M, Ferri M, Feingold D
Eur Arch Psychiatry Clin Neurosci
. 2025 Mar;
275(2):315-326.
PMID: 40035833
Between 8 and 22% of lifetime cannabis users develop Cannabis Use Disorder (CUD). It is the most frequent reason for first-time drug-related treatment admissions in Europe. Many countries have general...
3.
Hoch E, Hall W, Feingold D
Eur Arch Psychiatry Clin Neurosci
. 2025 Feb;
275(2):277-279.
PMID: 39951121
No abstract available.
4.
Feingold D, Gliksberg O, Brill S, Amit B, Lev-Ran S, Kushnir T, et al.
Addict Behav
. 2024 Aug;
158:108122.
PMID: 39128420
The use of Medicinal Cannabis (MC) for treating chronic pain is increasing, globally, yet the definition of problematic MC use remains unclear. Defining problematic use of cannabis in medical and...
5.
Donohue K, Rossi A, Deek M, Feingold D, Maloney Patel N, Jabbour S
Cancer J
. 2024 Jul;
30(4):245-250.
PMID: 39042775
Although total mesorectal excision (TME) remains the standard of care for rectal cancer, including early-stage T1/T2 rectal adenocarcinoma, local excision may be warranted for these early-stage tumors in a select...
6.
Stampf A, Schwarzkopf L, Batalla A, Feingold D, Fischer B, Hoch E
Eur Arch Psychiatry Clin Neurosci
. 2024 Jul;
275(2):365-378.
PMID: 38951248
Post-2000, the prevalence of cannabis consumption has been rising internationally. This paper investigates whether cannabis-related treatment demand in German outpatient addiction care facilities (OACFs) has been following this trend. Treatment...
7.
Feingold D, Neria Y, Tzur Bitan D
J Psychiatr Res
. 2024 Apr;
174:153-158.
PMID: 38631140
The October 7th, 2023, terror attacks in Israel were characterized by a scope and magnitude not previously known to Israeli citizens. The aim of this study was to examine the...
8.
Feingold D, Tzur Bitan D, Ferri M, Hoch E
Eur Arch Psychiatry Clin Neurosci
. 2024 Mar;
275(2):341-353.
PMID: 38493284
Treatment demand for Cannabis Use Disorder (CUD) has increased in the past decade in almost all European countries, and CUD is currently the most common reason for first-time drug-related treatment...
9.
Gliksberg O, Kushnir T, Sznitman S, Lev-Ran S, Brill S, Amit B, et al.
J Clin Nurs
. 2023 Feb;
32(17-18):5607-5618.
PMID: 36807590
Aims And Objectives: In this study, we systematically reviewed qualitative studies concerning patients' experience with medicinal cannabis (MC) use, to gain insight into the negative effects of MC. Background: Over...
10.
De Carvalho J, Lerner A, Feingold D
J Chiropr Med
. 2022 Nov;
21(4):322-326.
PMID: 36420369
Objective: The purpose of this study was to describe the management of 2 long-term users of cannabis with nutrition and psychotherapy. Clinical Features: A 28-year-old man presented with a medical...